John C.M. Farquhar Sells 22,562 Shares of Heartflow (NASDAQ:HTFL) Stock

Key Points

• Heartflow CEO John C.M. Farquhar sold 22,562 shares on Feb. 10 at an average of $27.46, netting about $619,553 and reducing his ownership by 3.67% to 591,656 shares (≈$16.25M).
• HTFL shares traded down to $27.30 that day (down $1.99) on elevated volume of ~2.30 million shares versus an average of ~1.55 million, signaling heavier trading activity around the insider transaction.
• Analysts maintain a consensus "Moderate Buy" rating with a $38.50 price target—five Buys, two Holds and one Sell—with several firms recently raising targets into the $38–$40 range.

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 22,562 shares of Heartflow stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $27.46, for a total value of $619,552.52. Following the sale, the chief executive officer directly owned 591,656 shares of the company's stock, valued at approximately $16,246,873.76. This trade represents a 3.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Heartflow Stock Performance

NASDAQ HTFL traded down $1.99 during trading on Tuesday, reaching $27.30. 2,297,584 shares of the stock traded hands, compared to its average volume of 1,549,832. Heartflow, Inc. has a fifty-two week low of $25.38 and a fifty-two week high of $41.22. The firm's 50-day moving average is $30.26.

Institutional Trading of Heartflow

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. TFC Financial Management Inc. acquired a new position in Heartflow during the third quarter worth $40,000. Legal & General Group Plc bought a new stake in Heartflow during the 3rd quarter worth about $59,000. Strs Ohio acquired a new position in shares of Heartflow during the 4th quarter worth about $99,000. Y Intercept Hong Kong Ltd bought a new position in shares of Heartflow in the 3rd quarter valued at about $234,000. Finally, Staley Capital Advisers Inc. acquired a new stake in shares of Heartflow in the fourth quarter valued at about $204,000.

Analyst Ratings Changes

Several research firms have weighed in on HTFL. Stifel Nicolaus lifted their target price on Heartflow from $35.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, November 13th. Wells Fargo & Company began coverage on Heartflow in a report on Wednesday, January 28th. They set an "overweight" rating and a $38.00 price objective on the stock. Weiss Ratings reiterated a "sell (d)" rating on shares of Heartflow in a research report on Monday, December 29th. Canaccord Genuity Group raised their target price on shares of Heartflow from $39.00 to $40.00 and gave the stock a "buy" rating in a report on Thursday, November 13th. Finally, JPMorgan Chase & Co. upped their price target on shares of Heartflow from $36.00 to $40.00 and gave the company an "overweight" rating in a report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $38.50.

Heartflow Company Profile

HeartFlow, Inc NASDAQ: HTFL is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.